Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00446784

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00446784. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224,535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate

Study identification

NCT ID: NCT00446784
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 20 participants

Conditions and interventions

Conditions

Arthritis, Rheumatoid

Interventions

CE-224,535 Drug
Methotrexate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2007 (Type not available)
Primary completion: Aug 2007 (Actual)
Completion: Aug 2007 (Actual)
Last update posted: May 23, 2011

2007

United States locations

U.S. sites: 5
U.S. states: 3
U.S. cities: 4

Facility	City	State	ZIP	Site status
Pfizer Investigational Site	Miami	Florida	33169	—
Pfizer Investigational Site	Ocala	Florida	34471	—
Pfizer Investigational Site	Ocala	Florida	34474	—
Pfizer Investigational Site	Kalamazoo	Michigan	49007	—
Pfizer Investigational Site	Ducansville	Pennsylvania	16635	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00446784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 23, 2011 · Synced Nov 13, 2026